AVH
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Avita Medical, Inc. is a commercial-stage regenerative medicine company focused on therapeutic acute wound care and skin restoration. The company develops technologies to treat burns, traumatic injuries, and other complex wounds, supporting wound preparation, closure, and healing. Its primary product, RECELL, is an autologous skin cell suspension system approved by the U.S. Food and Drug Administration for thermal burn wounds and full-thickness skin defects, utilizing Spray-On Skin Cells for point-of-care closure. In the United States, the company also markets Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO are CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan. The company serves physicians and healthcare facilities in the U.S., Europe, Australia, New Zealand, and Japan.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage avitamedical.com
Sector Healthcare IR page ir.avitamedical.com/news-releases/news-release-details/avita-medical-host-investor-webinar-briefing-12
Tags
regenerative medicine, wound care, burn treatment, skin restoration, autologous cell therapy, dermal matrix, biosynthetic wound matrix, acute wound management, RECELL, Spray-On Skin Cells, Cohealyx, PermeaDerm, RECELL GO
Press page avitamedical.com/press-releases

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue — 50.143M 34.421M 5.489M 942.708K 894.348K 722.05K 13.074M 2.406M 2.924M 4.859M 4.443M 2.964M
Net profit — -35.381M -26.665M -25.046M -12.99M -8.72M -5.605M -5.592M -4.616M -8.407M -8.094M -1.806M —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

AVITA Medical Reports Complete Cohealyx I Data Bull 5 Bear 0 Clinical/regulatory
Cleansing Notice Bull 0 Bear 0 Routine
Notification regarding unquoted securities - AVH Bull 0 Bear 0 Routine

Prompts

Avita Medical, Inc. (ticker RCEL), listed in Australia.

Company History

Date Change Detail
Dec 16, 2020 Renamed AVITA THERAPEUTICS, INC. → AVITA MEDICAL, INC.
Jul 6, 2020 Renamed AVITA MEDICAL, LTD. → AVITA THERAPEUTICS, INC.
Dec 31, 2019 Reporting currency Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

Securities

Ticker Type Class Market Exchange Last price Price date
RCEL Common share — US nasdaq 11.73 USD 2026-09-30
AVH canonical Common share — AU asx — —